Egenix Overview
- Year Founded
-
1991
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Egenix General Information
Description
Provider of cancer treatment services. The company operates as a biotechnology agency and is engaged in the research and development of cancer therapeutics. It's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers.
Contact Information
Website
www.egenixinc.com
Formerly Known As
Epigen
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Denan
Primary Office
- P.O. Box L
- Millbrook, NY 12545
- United States
+1 (845) 000-0000
Egenix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Egenix Patents
Egenix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2608041-A1 | Method for diagnosis of prostate cancer | Inactive | 12-May-2004 | 000000000000 | |
| US-20050272102-A1 | Method for diagnosis of prostate cancer | Inactive | 12-May-2004 | 000000000000 | 0 |
| AU-6102494-A | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy | Inactive | 05-Feb-1993 | 000000000000 | |
| CA-2154266-A1 | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy | Inactive | 05-Feb-1993 | 000000000000 | |
| DE-69432926-D1 | Humanes carcinoma antigen (hca), hca antibodies, hca immunoassays, recording methods and therapy | Inactive | 05-Feb-1993 | A61K39/00117 |